人福醫藥(600079.SH):聘任公司董事、副總裁鄧霞飛為公司總裁
格隆匯4月2日丨人福醫藥(600079.SH)公佈,公司於近日收到公司董事、總裁李傑的書面辭職報告,李傑由於工作分工調整提出辭去公司總裁職務。
公司董事會對李傑在任職總裁期間為公司發展所做出的貢獻表示衷心感謝。該事項不會對公司治理、日常管理、生產經營及償債能力造成影響,經公司於2020年4月2日召開的第九屆董事會第四十三次會議審議通過,由李傑擔任公司董事長,任期自董事會審議通過之日起至公司第九屆董事會任期屆滿為止,李傑在公司下屬子公司的任職保持不變。
根據《公司法》及《公司章程》的有關規定,公司第九屆董事會第四十三次會議審議通過了《關於聘任公司總裁的議案》,經公司董事長提名,公司董事會決定聘任公司董事、副總裁鄧霞飛為公司總裁,任期自董事會審議通過之日起至公司第九屆董事會任期屆滿時止,鄧霞飛不再擔任公司副總裁職務。
鄧霞飛,男,1963年12月出生,中國國籍,農工民主黨,工學博士,正高級工程師。歷任湖南藥業公司總經理,湖南省醫藥局產業開發辦主任,1998年3月至今任人福醫藥副總裁,2000年8月至今任人福醫藥董事,2001年2月至今任湖北葛店人福藥業有限責任公司董事長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.